The new lymphoma drug Polivy can be prescribed at general hospitals. According to related industries, ADC that combine with conventional BR therapy (Bendamustine/ Rituximab) treatments for diffuse large B-cell lymphoma (DLBCL) that have poor non-responsive prognosis of Roche.

However, Polivy is still a non-reimbursed drug. Roche applied insurance benefit earlier this year, but failed to pass HIRA's Cancer Drugs Benefit Appraisal Committee in April. Roche is attempting to register Polivy in the future. Diffuse large B-cell lymphoma, which accounts for the highest percentage of non-Hodgkin lymphoma, is a type of aggressive lymphoma that requires immediate treatment due to its fast progression. More than